Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
ALVO(NASDAQ:ALVO) REYKJAVIK, Iceland, June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-10, 2025. Alvotech will be meeting with investors on Tuesday, September 9, 2025, and Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday September 10, 2025, at 10:45 am EDT (14:45 GMT / 16:45 CET).
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
ALVO(NASDAQ:ALVO) REYKJAVIK, Iceland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-10, 2025. Alvotech will be meeting with investors on Tuesday, September 9, 2025, and Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday September 10, 2025, at 10:45 am EDT (14:45 GMT / 16:45 CET).
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
ALVOREYKJAVIK, Iceland and LONDON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission has approved Mynzepli® as a biosimilar to Eylea® (aflibercept), in a pre-filled syringe and vial.
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
ALVOREYKJAVIK, ICELAND and LONDON, UK (August 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission has approved Mynzepli® as a biosimilar to Eylea® (aflibercept), in a pre-filled syringe and vial.
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
ALVOREYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined the company as VP Investor Relations Scandinavia, based in Stockholm.
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
ALVOREYKJAVIK, Iceland, August 13, 2025 - Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on August 14, 2025, at 8:00 am ET (12:00 pm GMT).
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
ALVOREYKJAVIK, Iceland, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on August 14, 2025, at 8:00 am ET (12:00 pm GMT).
Alvotech And Dr. Reddy's Partner To Co-Develop Biosimilar To Keytruda, Targeting Global Oncology Markets
ALVODr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
ALVOAlvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.
Alvotech And Dr. Reddy's Sign Agreement To Co-Develop And Commercialize Biosimilar To Keytruda Worldwide
ALVOReported Earlier, Alvotech Raises SEK 750M (~$71.25M) Through Private Placement Of SDRs And Ordinary Shares To Swedish And Global Institutional Investors
ALVOAlvotech And Advanz Pharma Announced That The Companies Have Entered Into An Agreement To Expand Their Commercial Partnership To Cover Three Additional Biosimilar Candidates
ALVOWhy Is Teva Stock Trading Higher On Tuesday?
ALVOTeva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday
ALVO12 Health Care Stocks Moving In Wednesday's After-Market Session
ALVOAlvotech Raises FY2025 Sales Guidance from $570.00M-$670.00M to $600.00M-$700.00M vs $645.96M Est
ALVOAlvotech Q1 EPS $0.35 Beats $(0.11) Estimate, Sales $132.80M Beat $95.02M Estimate
ALVOAlvotech Expects Minimal Impact From Potential U.S. Tariffs, With Less Than 1% Effect On 2025 Product Revenues
ALVOAlvotech's Earnings Outlook
ALVOTeva Pharma And Alvotech Announce FDA Approval For SELARSDI Injection As Interchangeable With Reference Biologic Stelara
ALVOAlvotech FY 2024 GAAP EPS $(0.87) Misses $(0.55) Estimate, Sales $492.00M Beat $455.53M Estimate
ALVOAlvotech, Kashiv Biosciences And Advanz Pharma Announced That The UK Medicines And Healthcare Products Regulatory Agency Confirms Acceptance Of Marketing Authorization Application For Proposed Biosimilar To Xolair (Omalizumab)
ALVOAlvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D Deal
ALVOAlvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities and expanding into Sweden.
Alvotech Acquires Xbrane's R&D Operations And Biosimilar Candidate XB003 In $27M Deal, Establishing Swedish Hub
ALVOAlvotech And Dr. Reddy's Announce FDA Acceptance Of Biologic License Application For AVT03
ALVOTeva Pharmaceuticals And Alvotech Announce U.S. Availability of SELARSDI (Ustekinumab-aekn) Injection, A Biosimilar To Stelara For Treatment Of Psoriatic Arthritis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Pediatric Plaque Psoriasis And Pedi
ALVOThe FDA Has Accepted For Review A Biologics License Application For AVT06, Alvotech's Proposed Biosimilar To Teva Pharmaceuticals' Eylea (Aflibercept), A Biologic Used To Treat Eye Disorders, The Process To Obtain Regulatory Approval Is Anticipated To Be
ALVOUBS Initiates Coverage On Alvotech with Buy Rating, Announces Price Target of $18
ALVOApplied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
ALVOAlvotech Joins Nasdaq Biotech Index, Effective Today
ALVOAlvotech shares are trading higher after the company reported better-than-expected Q3 sales results.
ALVOAlvotech Says EMA Accepted Marketing Authorization Application For AVT05, Proposed Biosimilar To Simponi (Golimumab), A Biologic Used To Treat Several Chronic Inflammatory Diseases
ALVOAlvotech Now Sees FY24 Revenue Of $400M-$500M, Est $318.575M
ALVOAlvotech Q1 2024 Sales $36.894M Miss $45.000M Estimate
ALVOAlvotech Q1 2024 GAAP EPS $(0.89) Up From $(1.24) YoY
ALVOStocks Hold Steady On Mixed Fed Remarks, First Solar Rallies, Bitcoin Falls Below $70,000: What's Driving Markets Tuesday?
ALVOIt’s a rather quiet session on Tuesday, with major U.S. averages trading around the flatline at midday trading in New York.
Alvotech And Dr. Reddy's Enter Collaboratoin For Commercialization Of Prolia & Xgeva Biosimilar, AVT03
ALVOReported Earlier, Teva And Alvotech Announce U.S. Launch Of Simlandi (adalimumab-ryvk), The First Interchangeable High-Concentration, Citrate-Free Biosimilar To Humira
ALVO